Curis to Present at 2022 Jefferies Global Healthcare Conference
Curis, a biotechnology firm listed under NASDAQ: CRIS, will present a company overview at the 2022 Jefferies Healthcare Conference on June 9, 2022, at 11:00 a.m. in New York. James Dentzer, President and CEO, will lead the presentation. A live webcast will be available on the Curis website, with a replay accessible for 90 days post-event. Curis focuses on cancer therapeutics, holding licenses for various innovative treatments, including emavusertib, currently in clinical trials, despite a partial hold by the FDA on certain trials. For more details, visit www.curis.com.
- None.
- None.
LEXINGTON, Mass., June 2, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that James Dentzer, President and Chief Executive Officer of Curis, will present a company overview at the 2022 Jefferies Healthcare Conference on Thursday, June 9, 2022 at 11:00 a.m. in New York, NY.
A live webcast of the presentation will be available under "Events & Presentations" in the Investors section of the Company's website at www.curis.com. A replay of the webcast will be available on the Curis website for 90 days following the event.
Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, emavusertib (CA-4948). Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma trial, in patients with hematologic malignancies, such as non-Hodgkins lymphoma and other B cell malignancies, both as a monotherapy and in combination with BTK inhibitor ibrutinib, and the Phase 1/2 TakeAim Leukemia trial in patients with acute myeloid leukemia and myelodysplastic syndrome, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. The FDA has placed a partial clinical hold on the TakeAim Leukemia and TakeAim Lymphoma trials during which no new patients will be enrolled, and current study participants benefiting from treatment may continue to be treated with emavusertib at doses of 300mg BID or lower. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.
For more information, visit Curis's website at www.curis.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-at-2022-jefferies-global-healthcare-conference-301559925.html
SOURCE Curis, Inc.
FAQ
When will Curis present at the Jefferies Healthcare Conference?
Who is presenting for Curis at the conference?
Where can I watch the Curis presentation live?
What is the focus of Curis, Inc.?
What clinical trials is Curis currently conducting?
What issues is Curis facing with its clinical trials?
